Log in

NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Forecast & News

$5.32
+0.07 (+1.33 %)
(As of 02/23/2020 04:00 PM ET)
Today's Range
$5.03
Now: $5.32
$5.35
50-Day Range
$0.51
MA: $0.78
$5.32
52-Week Range
$4.65
Now: $5.32
$18.50
Volume274,416 shs
Average Volume202,844 shs
Market Capitalization$85.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.41 million
Book Value($2.17) per share

Profitability

Net Income$-5,330,000.00

Miscellaneous

Employees17
Market Cap$85.55 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.


AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals's stock reverse split on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.07 by $0.95. The biopharmaceutical company earned $25.72 million during the quarter. AVEO Pharmaceuticals had a net margin of 120.85% and a negative return on equity of 561.43%. View AVEO Pharmaceuticals' Earnings History.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for AVEO Pharmaceuticals.

What price target have analysts set for AVEO?

3 equities research analysts have issued 12 month price targets for AVEO Pharmaceuticals' shares. Their forecasts range from $17.50 to $20.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 252.4% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.

What is the consensus analysts' recommendation for AVEO Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AVEO Pharmaceuticals.

What are Wall Street analysts saying about AVEO Pharmaceuticals stock?

Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AVEO got a huge boost from the approval for Fotivda in Europe for the first-line treatment of advanced renal cell carcinoma. However, it faced a major setback when it had to delay the new drug application filling for Fotivda in the United States. In September 2019, AVEO announced updated data from the second prespecified analysis of overall survival from the phase III study on Fotivda. The results included an OS hazard ratio of less than one, favoring Fotivda. Failure to receive regulatory approvals or termination of any deal would significantly hurt the stock in future. AVEO receives royalties from Fotivda sales in certain European countries. This is another revenue driver. Shares have underperformed the industry in the past year. Estimates looks stable ahead of Q4 earnings. AVEO has a mixed record earnings surprises in recent quarters." (2/21/2020)
  • 2. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Media stories about AVEO stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for AVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 16,400,000 shares, a decline of 5.0% from the January 15th total of 17,270,000 shares. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is currently 8.6 days. Approximately 12.2% of the company's shares are sold short. View AVEO Pharmaceuticals' Current Options Chain.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Novavax (NVAX), Amarin (AMRN), Alibaba Group (BABA), Canopy Growth (CGC), Bellicum Pharmaceuticals (BLCM) and Opko Health (OPK).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
  • Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 59)
  • Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Jacobs Levy Equity Management Inc. (0.90%), Geode Capital Management LLC (0.61%), Marshall Wace LLP (0.18%), Virtu Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.

Which major investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for AVEO Pharmaceuticals.

Which major investors are buying AVEO Pharmaceuticals stock?

AVEO stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Marshall Wace LLP and Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $5.32.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $85.55 million and generates $5.41 million in revenue each year. The biopharmaceutical company earns $-5,330,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.View Additional Information About AVEO Pharmaceuticals.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  367 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  716
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel